ATE538807T1 - Behandlung von sinusitis-assoziierten beschwerden mit botulinum toxin - Google Patents

Behandlung von sinusitis-assoziierten beschwerden mit botulinum toxin

Info

Publication number
ATE538807T1
ATE538807T1 AT04718359T AT04718359T ATE538807T1 AT E538807 T1 ATE538807 T1 AT E538807T1 AT 04718359 T AT04718359 T AT 04718359T AT 04718359 T AT04718359 T AT 04718359T AT E538807 T1 ATE538807 T1 AT E538807T1
Authority
AT
Austria
Prior art keywords
botulinum toxin
treating sinusitis
associated affairs
affairs
treating
Prior art date
Application number
AT04718359T
Other languages
English (en)
Inventor
Gary Borodic
Martin Acquadro
Original Assignee
Botulinum Toxin Res Associates Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Botulinum Toxin Res Associates Inc filed Critical Botulinum Toxin Res Associates Inc
Application granted granted Critical
Publication of ATE538807T1 publication Critical patent/ATE538807T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AT04718359T 2003-03-06 2004-03-08 Behandlung von sinusitis-assoziierten beschwerden mit botulinum toxin ATE538807T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45303703P 2003-03-06 2003-03-06
PCT/IB2004/000635 WO2004078201A1 (en) 2003-03-06 2004-03-08 Treatment of sinusitis related chronic facial pain and headache with botulinum toxin

Publications (1)

Publication Number Publication Date
ATE538807T1 true ATE538807T1 (de) 2012-01-15

Family

ID=32962756

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04718359T ATE538807T1 (de) 2003-03-06 2004-03-08 Behandlung von sinusitis-assoziierten beschwerden mit botulinum toxin

Country Status (17)

Country Link
US (1) US8691769B2 (de)
EP (1) EP1599221B1 (de)
JP (1) JP2007528352A (de)
KR (1) KR20050109969A (de)
CN (1) CN1874784B (de)
AT (1) ATE538807T1 (de)
AU (1) AU2004216904B2 (de)
BR (1) BRPI0408131A (de)
CA (1) CA2518157C (de)
CR (1) CR7975A (de)
ES (1) ES2381091T3 (de)
IL (1) IL170157A (de)
MX (1) MXPA05009425A (de)
NO (1) NO20054580L (de)
NZ (1) NZ541779A (de)
WO (1) WO2004078201A1 (de)
ZA (1) ZA200506715B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2380662T3 (es) 2002-11-21 2012-05-17 Ira Sanders Neurotoxina clostridial para su uso en el tratamiento de congestión nasal
CN100525831C (zh) * 2002-12-20 2009-08-12 肉毒素研究同仁股份有限公司 改进的药用肉毒杆菌毒素组合物
WO2004076634A2 (en) * 2003-02-24 2004-09-10 Ira Sanders Cell membrane translocation of regulated snare inhibitors , compositions therefor, and methods for treatment of disease
US7670608B2 (en) * 2003-03-06 2010-03-02 Botulinum Toxin Research Associates, Inc. Selection of patients with increased responsiveness to botulinum toxin
MXPA05009424A (es) * 2003-03-06 2006-02-10 Botulinum Toxin Res Ass Inc Tratamiento de chalazion cronico y hordeolum con la toxina botulinica.
US6838434B2 (en) * 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
EP2264030A1 (de) 2003-10-17 2010-12-22 Incyte Corporation Substituierte cyclische Hydroxamate als Inhibitoren von Matrixmetalloproteinasen
US8734810B2 (en) * 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US20050191321A1 (en) * 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US9078892B2 (en) * 2004-02-26 2015-07-14 Allergan, Inc. Methods for treating pain and for treating a medication overuse disorder
US20100266638A1 (en) 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US7749515B2 (en) 2005-02-01 2010-07-06 Allergan, Inc. Targeted delivery of botulinum toxin to the sphenopalatine ganglion
US7655244B2 (en) * 2005-02-01 2010-02-02 Allergan, Inc. Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
US20150258183A1 (en) 2006-06-07 2015-09-17 Botulinum Toxin Research Associates, Inc. Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
JP5233399B2 (ja) * 2008-05-13 2013-07-10 ライオン株式会社 口腔スプレー用組成物及び口腔用製剤
EP2364168A1 (de) 2008-12-04 2011-09-14 Botulinum Toxin Research Associates, Inc. Verlängerte botulinustoxin-formulierung zur anwendung bei menschen oder säugetieren
WO2011084507A1 (en) * 2009-12-15 2011-07-14 Ira Sanders Treatment of nasal and sinus disorders
US8722060B2 (en) * 2012-05-23 2014-05-13 William J. Binder Method of treating vertigo
MX358613B (es) 2012-03-12 2018-08-27 J Binder William Tratamiento de dolor de cabeza por migraña con neurotoxina presinaptica.
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
CA2889833A1 (en) 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and methods for safe treatment of rhinitis
WO2015200322A1 (en) * 2014-06-23 2015-12-30 Northwestern University Methods of treating or ameliorating migraine
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
KR20170036928A (ko) 2015-09-24 2017-04-04 울산대학교 산학협력단 IKKε 억제제를 유효성분으로 함유하는 만성 부비동염 예방 또는 치료용 약학조성물
US10456419B2 (en) 2017-02-27 2019-10-29 Payman Sadeghi Method for treating migraine headaches
US10932711B2 (en) 2017-02-27 2021-03-02 Payman Sadeghi Method and system for neurohydrodissection
EP3632450A4 (de) * 2017-05-24 2021-03-17 ATGC Co., Ltd. Pharmazeutische zusammensetzung zur behandlung von fussschmerzerkrankungen mit botulinumtoxin und hyaluronsäure und verfahren zur behandlung von fussschmerzerkrankungen damit
RU2740268C1 (ru) * 2020-08-03 2021-01-12 Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр реабилитации и курортологии» Министерства здравоохранения Российской Федерации (ФГБУ «НМИЦ РК» Минздрава России) Способ лечения пациентов среднего возраста с хроническим болевым синдромом при дорсопатиях вертеброгенного и невертеброгенного генеза
GB202116795D0 (en) * 2021-11-22 2022-01-05 Ipsen Biopharm Ltd Treatment of visceral pain

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4940728A (en) * 1985-05-17 1990-07-10 Postley John E Treatment for sino-nasal congestion
US5034461A (en) 1989-06-07 1991-07-23 Bausch & Lomb Incorporated Novel prepolymers useful in biomedical devices
US5478565A (en) * 1990-03-27 1995-12-26 Warner-Lambert Company Treatment of sinus headache
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
CA2138020C (en) 1992-06-23 1999-02-16 Eric A. Johnson Pharmaceutical composition containing botulinum b complex
US5401452A (en) 1993-07-26 1995-03-28 Environmental Protection Polymers, Inc. Methods for encapsulating waste and products thereof
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
EP1421948B1 (de) * 1993-12-28 2008-10-08 Allergan, Inc. Verwendung von Botulinum Toxine gegen Schwitzen bei Menschen
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US20040126396A1 (en) 1993-12-28 2004-07-01 Allergan, Inc. Botulinum toxin treatment for strabismus
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US5670484A (en) 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
AU2431995A (en) 1994-05-09 1995-11-29 William J. Binder Method for reduction of headache pain
AU2907695A (en) 1994-08-08 1996-03-07 Wisconsin Alumni Research Foundation Purification and pharmaceutical compositions containing type g botulinum neurotoxin
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
CA2505933C (en) 1997-07-15 2008-09-30 Richard A. Schmidt Use of botulinum toxin for treating urinary incontinence
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US5849929A (en) * 1997-09-26 1998-12-15 Uniroyal Chemical Company, Inc. Process for the preparation of imidazoline nitroxyl
US7537773B1 (en) * 1998-08-25 2009-05-26 Botulinum Toxin Research Associates, Inc. Chemodenervating pharmaceutical as anti-inflammatory agent
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6265379B1 (en) 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US6139845A (en) 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US6429189B1 (en) 1999-12-10 2002-08-06 Botulinum Toxin Research Associates, Inc. Cytotoxin (non-neurotoxin) for the treatment of human headache disorders and inflammatory diseases
US6143306A (en) 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6641820B1 (en) * 2000-01-19 2003-11-04 Allergan, Inc. Clostridial toxin derivatives and methods to treat pain
US7780967B2 (en) 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US6358513B1 (en) 2000-02-15 2002-03-19 Allergan Sales, Inc. Method for treating Hashimoto's thyroiditis
US6649161B1 (en) 2000-02-22 2003-11-18 Allergan, Inc. Method for treating hypocalcemia
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6306403B1 (en) 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
JP3860403B2 (ja) 2000-09-25 2006-12-20 株式会社東芝 半導体メモリ装置
US6423319B1 (en) 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US20020192239A1 (en) 2001-01-09 2002-12-19 Borodic Gary E. Use of botulinum toxin for the treatment of chronic facial pain
WO2003000193A2 (en) 2001-06-21 2003-01-03 Surromed, Inc. Covalent coupling of botulinum toxin with polyethylene glycol
CA2369810C (en) 2002-01-30 2007-08-07 1474791 Ontario Limited Method of treating pain
US20040138097A1 (en) * 2002-11-01 2004-07-15 Bahman Guyuron Method and treatment for treating and preventing pain associated with compression of a nerve
ES2380662T3 (es) * 2002-11-21 2012-05-17 Ira Sanders Neurotoxina clostridial para su uso en el tratamiento de congestión nasal
US6838434B2 (en) * 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache

Also Published As

Publication number Publication date
MXPA05009425A (es) 2006-02-10
KR20050109969A (ko) 2005-11-22
EP1599221B1 (de) 2011-12-28
ES2381091T3 (es) 2012-05-23
NO20054580D0 (no) 2005-10-05
CA2518157C (en) 2018-09-04
CN1874784B (zh) 2010-06-09
BRPI0408131A (pt) 2006-03-01
US20040247606A1 (en) 2004-12-09
ZA200506715B (en) 2007-05-30
NO20054580L (no) 2005-12-06
AU2004216904B2 (en) 2009-12-24
CN1874784A (zh) 2006-12-06
AU2004216904A1 (en) 2004-09-16
WO2004078201A1 (en) 2004-09-16
IL170157A (en) 2012-12-31
EP1599221A1 (de) 2005-11-30
CR7975A (es) 2008-09-02
US8691769B2 (en) 2014-04-08
NZ541779A (en) 2008-01-31
JP2007528352A (ja) 2007-10-11
CA2518157A1 (en) 2004-09-16

Similar Documents

Publication Publication Date Title
ATE538807T1 (de) Behandlung von sinusitis-assoziierten beschwerden mit botulinum toxin
WO2003089457A3 (en) Peptide inhibitors of protein kinase c ϝ for pain management
DE60141230D1 (de) Verwendung von Botulinum Toxin zur Behandlung von neuralgischen Schmerzen
ATE318812T1 (de) Thiazolyl-inhibitoren von tyrosinkinasen der tec- familie
DE69924641D1 (de) Behandlung von asthma anhand von mek-inhibitoren
NO20070052L (no) Fremgangsmate for behandling av multippel sklerose
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
CY1107640T1 (el) Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη
DE602005026276D1 (de) Myricitrin verbindungen zur behandlung von schlafstörungen
ATE315390T1 (de) Zyklische polyamine zur behandlung der thrombozytopenie
DE60310400D1 (de) Botulinustoxine zur behandlung von priapismus
CY1108540T1 (el) Ταυτοποιηση θεραπευτικων ενωσεων
WO2002078639A3 (en) A method of treating proliferative diseases using eg5 inhibitors
ATE345793T1 (de) Behandlung von xanthom mittels azetidinon- derivate als hemmer der sterol absorption
DE60218153D1 (de) Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges
DE60219658D1 (de) Verfahren zur prävention und behandlung von infektionen mit dem flavivirus bei tieren
ATE411036T1 (de) Verwendung von aplidine in der behandlung von pankreaskrebs
ATE406171T1 (de) Aplidine zur behandlung von multiplem myelom
DE60231896D1 (de) Zusammensetzungen und verfahren zur erhöhung der compliance mit therapien unter verwendung von aldehyddehydrogenase-hemmern und zur behandlung von alkoholsmus
DE60141596D1 (de) Transdermales system zur verabreichung von loratadin und dessen verwendung
DE60109594D1 (de) R-eliprodil zur behandlung von glaucoma
ATE322898T1 (de) Inhibitoren von mycobakterien
DE602004022423D1 (de) Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz
ATE501760T1 (de) E5564 zur verwendung in der behandlung von allograft-abstossung oder host-versus-graft- erkrankungen
DE69924385D1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung